ReviewPsychopharmacology2022
Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.
Review in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds.European psychiatry : the journal of the Association of European Psychiatrists · 2024Pooled it
- Comparing affective bias modification by first- and second-generation antidepressants in male rats using a translational behavioural task.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Venlafaxine and Delirium: Understanding the Association.Current neuropharmacology · 2026Review
- Comparative Analysis of Antidepressant Mechanisms and Side Effects: Network Pharmacology and Molecular Docking Study of Amitriptyline, Mirtazapine, and Escitalopram for Treating Major Depressive Disorder.Depression and anxiety · 2026Article
- Phenotype-guided selection of venlafaxine and topiramate for vestibular migraine: a narrative review.Frontiers in neuroscience · 2026Review
- Low-dose venlafaxine-induced erythema multiforme: a case report.Journal of medical case reports · 2025Article
- Examining memory reconsolidation as a mechanism of nitrous oxide's antidepressant action.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Review
- NeuropsychopharmARCology: Shaping Neuroplasticity through Arc/ Arg3.1 Modulation.Current neuropharmacology · 2025Review
- Reassessing the Role of Mind-Regulating Acupuncture in Post-Stroke Depression: Promising but Not Yet Definitive [Letter].Neuropsychiatric disease and treatment · 2025Article
- Personalized venlafaxine dose prediction using artificial intelligence technology: a retrospective analysis based on real-world data.International journal of clinical pharmacy · 2024Article
- Effects of Antidepressants on Sleep in Post-traumatic Stress Disorder: An Overview of Reviews.Current neuropharmacology · 2024Review
- Venlafaxine's effect on resilience to stress is associated with a shift in the balance between glucose and fatty acid utilization.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- Enriched environmental exposure reduces the onset of action of the serotonin norepinephrin reuptake inhibitor venlafaxine through its effect on parvalbumin interneurons plasticity in mice.Translational psychiatry · 2023Article
- Chronic N-Acetyl-Cysteine Treatment Enhances the Expression of the Immediate Early GeneInternational journal of molecular sciences · 2023Article
- Treatment of Persistent Idiopathic Dentoalveolar Pain with Venlafaxine: A Multicentric Retrospective Study on Its Effectiveness and Safety.Journal of pain research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depression (MD) is one of the most common psychiatric disorders worldwide. Currently, the first-line treatment for MD targets the serotonin system but these drugs, notably the selective serotonin reuptake inhibitors, usually need 4 to 6 weeks before the benefit is felt and a significant proportion of patients shows an unsatisfactory response. Numerous treatments have been developed to circumvent these issues as venlafaxine, a mixed serotonin-norepinephrine reuptake inhibitor that binds and blocks both the SERT and NET transporters. Despite this pharmacological profile, it is difficult to have a valuable insight into its ability to produce more robust efficacy than single-acting agents. In this review, we provide an in-depth characterization of the pharmacological properties of venlafaxine from in vitro data to preclinical and clinical efficacy in depressed patients and animal models of depression to propose an indirect comparison with the most common antidepressants. Preclinical studies show that the antidepressant effect of venlafaxine is often associated with an enhancement of serotonergic neurotransmission at low doses. High doses of venlafaxine, which elicit a concomitant increase in 5-HT and NE tone, is associated with changes in different forms of plasticity in discrete brain areas. In particular, the hippocampus appears to play a crucial role in venlafaxine-mediated antidepressant effects notably by regulating processes such as adult hippocampal neurogenesis or the excitatory/inhibitory balance. Overall, depending on the dose used, venlafaxine shows a high efficacy on depressive-like symptoms in relevant animal models but to the same extent as common antidepressants. However, these data are counterbalanced by a lower tolerance. In conclusion, venlafaxine appears to be one of the most effective treatments for treatment of major depression. Still, direct comparative studies are warranted to provide definitive conclusions about its superiority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.